Performance Aligns with Analyst Projections Amidst Strategic Clinical Advancements
MeiraGTx Holdings ( NASDAQ:MGTX ) First Quarter 2024 Results Key Financial Results Revenue: US$697.0k (down 79% from 1Q...
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Received $50 million milestone following initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) - Clinical development milestones met and remain on track for the re